Status:
COMPLETED
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Leukemia
Eligibility:
All Genders
15+ years
Brief Summary
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors predict response in patients previously treated with interleukin-2. PURPOSE: This lab...
Detailed Description
OBJECTIVES: * Correlate the in vitro lysis of autologous pre-treatment leukemic blast cells by interleukin-2 (IL-2)-expanded natural killer (NK) cells with relapse-free survival of patients with acut...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia
- Prior treatment with interleukin-2 required
- Previously enrolled on CLB-9621, CLB-9720, or CALGB-19808
- Previously consented to companion Leukemia Tissue Bank Protocol CALGB-9665 and stored the following specimens:
- Bone marrow blast cells procured at diagnosis and at relapse (when available)
- Peripheral blood mononuclear cells obtained in remission
- PATIENT CHARACTERISTICS:
- Age
- 15 and over
Exclusion
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
451 Patients enrolled
Trial Details
Trial ID
NCT00896701
Start Date
January 1 2004
End Date
April 1 2014
Last Update
July 13 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kinston Medical Specialists
Kinston, North Carolina, United States, 28501
2
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210-1240